Therapeutic Drugs and Delivery Strategies for Gastrointestinal Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 79

Special Issue Editors


E-Mail Website
Guest Editor
Department of Chemical Engineering and Adelson School of Medicine, Ariel University, Ariel 4070000, Israel
Interests: targeted drug delivery; peptide-drug-conjugates; Cellular immunotherapy; animal models of cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pediatrics, Seattle Children’s Hospital, University of Washington, 4800 Sandpoint Way NE, Seattle, WA 98105, USA
Interests: therapeutics in nflammatory bowel disease; eosinophilic esophagitis; gastrointestinal disease

Special Issue Information

Dear Colleagues,

Ailments of the gastrointestinal (GI) tract are commonly reported across the world in both adult and pediatric populations. The GI tract is home to a complex system of immune cells collectively called the mucosal immune system. In both states of health and disease, the mucosal immune system plays a crucial role in how the gastrointestinal tract operates on a daily basis. The therapies and pharmacologic agents used to treat mucosal diseases, such as inflammatory bowel disease, Celiac disease, and eosinophilic and non-eosinophilic diseases, have improved in recent years. These newer agents, drug dosages, therapy forms, and therapeutic preparation still constitute areas of exploration and discovery. As science advances, the clinical application and placement of these therapies will be vital to understand as we begin to tailor individual therapy to each patient’s disease.

Prof. Dr. Michael A. Firer
Dr. Hengqi Zheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted therapy in drug delivery
  • biologic therapies in inflammatory bowel disease (e.g., special dosages, administration and delivery)
  • biologic therapies in eosinophilic esophagitis (e.g., special dosages, administration and delivery)
  • eosinophilic gastrointestinal disease

Published Papers

This special issue is now open for submission.
Back to TopTop